{"title":"Lots of enthusiasm, lots of questions.","authors":"Michael D Dalzell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"10-4"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138390/pdf/bth08_2p010.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Value-based benefit design is all the rage, but applying it to biologics is complicated. Several issues must be addressed if VBBD is to rule this frontier.